52P - Combined chemotherapy with etoposide, irinotecan plus cisplatin compared with topotecan monotherapy as the second-line treatment in sensitive relap...

Date 07 May 2017
Event ELCC 2017
Session Poster Display Session
Topics Small Cell Lung Cancer
Thoracic Malignancies
Presenter Hongyan Wang
Citation Annals of Oncology (2017) 28 (suppl_2): ii17-ii20. 10.1093/annonc/mdx088
Authors H. Wang
  • Internal Medicine, Henan Provincial Anti-Cancer Hospital, 450008 - Zhengzhou/CN

Abstract

Background

Topotecan is currently the only drug approved by US Food and Drug Administration (FDA) for treatment of relapsed small-cell lung cancer (SCLC) patients. We did this study to attempt to investigate whether combined chemotherapy with etoposide, irinotecan plus cisplatin (PEI) was superior to topotecan alone as second-line treatment for sensitive relapsed SCLC patients.

Methods

Between January 2009 and November 2015, a total of 82 relapsed SCLC patients were admitted to the affiliated Cancer Hospital of Zhengzhou University in this retrospective analysis. Among them, 44 patients were treated with combined PEI chemotherapy, while 38 patients were treated with topotecan monotherapy. Disease control rates (DCR), progression-free survival (PFS), overall survival (OS) and adverse reaction were recorded.

Results

A total of 82 patients were analyzed. The patients treated with combined chemotherapy had longer median overall survival (OS) (16.3 months vs 10.1 months) than those treated with topotecan (P = 0.001), and median progression-free survival (PFS) time was slightly but significantly longer (6.2 months vs 4.1 months), than the topotecan group. Compared with the topotecan group, more common grade 3 or 4 adverse events were recorded for the combination chemotherapy group, including leucopenia, anaemia, thrombocytopenia. Grade 3-4 non-hematological toxicity was not common. When compared with younger patients, combined chemotherapy-treated patients (≥ 68 years of age) experienced higher rates of leucopenia, anemia, thrombocytopenia and fatigue. Serious adverse events were reported in two patients in the topotecan group and seven patients in the combination group. Two treatment-related deaths (one each of pulmonary infection and pneumonitis) occurred in the combination group, one treatment-related death (pneumonitis) occurred in the topotecan group.

Conclusions

Combined chemotherapy with etoposide, irinotecan plus cisplatin (PEI) is not inferior to topotecan monotherapy as the second-line treatment.

Clinical trial identification

none

Legal entity responsible for the study

None

Funding

The National Natural Science Foundation of China (No.81272600)

Disclosure

The author has declared no conflicts of interest.